UNSPSC 51161708: Desoxyribonuclease or dornase alfa

This classification denotes an enzyme replacement preparation with the molecular formula C1321H1995N339O396S9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 953A26OA1Y, more generally known as dornase alfa. European Medicines Agency schedules dornase alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06373MIG. The term DORNASE ALFA is an International Non-Proprietary Name or INN. Most nations schedule dornase alfa under HS 35079090 and SITC 51691.

As of Q4 2014, DORNASE ALFA remains the US FDA Preferred Term for this commodity. Dornase alfa bears US NLM identifiers UMLS ID C1135662 and NCI Concept Code C81664. SMILES: NONE.

UNSPSC 51161708 Desoxyribonuclease or dornase alfa is a Commodity code that in recent state and local procurement activity captures biological and chemical products used in municipal wastewater treatment and multistate pharmaceutical supply agreements, though the posted opportunities show minimal actual procurement under the nominal enzyme/pharmaceutical scope. The City of Tampa's Wastewater Department solicited technical grade phosphoric acid and liquid enzymes for pump station operations under this code, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted a generic multi-source pharmaceuticals and over-the-counter products RFP under the same code. State and local issuing bodies using this code include municipal wastewater utilities and cooperative purchasing alliances serving multiple states and local government facilities. The work itself spans chemical treatment supplies for infrastructure operations and pharmaceutical distribution through authorized wholesaler networks.

Recent activity concentrates in Florida and Minnesota. The City of Tampa's wastewater procurement (Solicitation 26P00135, IFB due April 1, 2026) sought approximately 50 drums of 55-gallon technical grade phosphoric acid annually and 12 drums of liquid enzymes, with an estimated contract value of $50,000 and award to the lowest responsive, responsible bidder meeting manufacturer or authorized distributor status. The Minnesota Department of Administration's MMCAP cooperative (Solicitation S1070000015802, RFP due March 26, 2026) established multi-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with 75 percent weight on price competitiveness and a two-year initial term effective July 1, 2026. Neither opportunity carried set-asides for small or disadvantaged businesses. The code shows sparse recent activity overall, and the mix of wastewater treatment chemicals and generic pharmaceuticals suggests potential code-classification misalignment with the nominal desoxyribonuclease/dornase alfa definition.